National cancer institute-supported cancer chemoprevention research: Coming of age

Journal of Clinical Oncology

Volumn 17, Issue 11 SUPPL., 1999, Pages 53-62

  McCaskill Stevens, Worta ^a   Hawk, Ernest T ^a   Flynn, Patrick J ^a   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PREVENTION; CANCER RESEARCH; CONFERENCE PAPER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; ONCOLOGY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH;

BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; RESEARCH SUPPORT; TAMOXIFEN; UNITED STATES;

EID: 0032726687     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 12:851-873, 1994
2. Lippman SM, Lee JJ, Sabichi AL: Cancer chemoprevention: Progress and promise. J Natl Cancer Inst 90:1514-1528, 1998
3. Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996
4. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group: The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035, 1994
5. Clark LC, Combs GF Jr, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276:1957-1963, 1996
6. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101, 1998
7. Moon TE, Levine N, Cartmel B, et al: Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 6:949-956, 1997
8. Blot WJ, Li JY, Taylor PR, et al: Linxian nutrition intervention trials: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85:1483-1492, 1993
9. Greenberg ER, Baron JA, Stukel TA, et al: A clinical trial of beta-carotene to prevent basal-cell and squamous-cell cancers of the skin: The Skin Cancer Prevention Study Group. N Engl J Med 323:789-795, 1990
10. Li J-Y, Taylor PR, Li B, et al: Nutrition intervention trials in Linxian, China: Multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 85:1492-1498, 1993
11. Hennekens CH, Burning JE, Manson JE, et al: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145-1149, 1996
12. Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352:93-97, 1998
13. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999
14. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
15. Lippraan SM, Lee JJ, Karp DD, et al: Phase III Intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage-I non-small cell lung cancer (NSCLC): Interim Report of NCI #191-0001. Proc Am Soc Clin Oncol 17:456a, 1998 (abstr 1753)
16. Khuri FR, Lee JJ, Winn RJ, et al: Interim analysis of randomized chemoprevention trial of HNSCC. Proc Am Soc Clin Oncol 18:389a, 1999 (abstr 1503)
17. FDA approves tamoxifen for "reduction in incidence," avoids word "prevention." Cancer Lett 24:1-4, 1998
18. Chlebowski RT, Collyar DE, Somerfield MR, et al: American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene. J Clin Oncol 17:1939-1955, 1999
19. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
20. Early Breast Cancer Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
21. Wang X-D, Liu C, Bronson RT, et al: Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst 91:60-66, 1999
22. Paolini M, Cantelli-Forti G, Perocco P, et al: Co-carcinogenic effect of beta-carotene. Nature 398:760-761, 1999
23. Mayne ST, Lippman SM. Retinoids and carotenoids, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 585-599
24. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA 281:2189-2197, 1999
25. Westfall PH, Young SS: Resampling-Based Multiple Testing. New York, NY, John Wiley, 1993
26. Heinonen OP, Albanes D, Virtamo J, et al: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440-446, 1998
27. Sturmer T, Glynn RJ, Lee IM, et al: Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128:713-720, 1998
28. Baron JA, Beach M, Mandel JS, et al: Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 340:101-107, 1999
29. Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993
30. Rigau J, Pique JM, Rubio E, et al: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115:952-954, 1991
31. Hong WK, Endicott J, Itri LM, et al: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986
32. Lippman SM, Batsakis JG, Toth BB, et al: Comparison of low-dose isotretinoin with beta-carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1993
33. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
34. Yokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
35. Lotan R, Xu X-C, Lippman SM, et al: Suppression of retinoic acid receptor beta in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 332:1405-1410, 1995
36. Mao L, Lee JS, Fan YH, et al: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 2:682-685, 1996
37. Lippman SM, Shin DM, Lee JJ, et al: p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 55:16-19, 1995
38. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al: Phenotype and genotype in advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 90:1545-1551, 1998
39. Xu X-C, Zile MH, Lippman SM, et al: Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res 55:5507-5511, 1995
40. Mao L, El-Naggar AK, Fan YH, et al: Telomerase activity in the pathogenesis of head and neck squamous cell carcinoma. Cancer Res 56:5600-5604, 1996
41. INK4a in oral premalignant lesions. Oncogene 14:1799-1803, 1997
42. Sun S-Y, Li W, Yue P, et al: Mediation of N-(4-hydroxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 59:2493-2498, 1999
43. Steele VE, Sharma S, Mahta R, et al: Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J Cell Biochem 268:29-53, 1996
44. Rudin CM, Recant W, Bennett P, et al: Preliminary report: Adenovirus ONYX-015 administered by mouthwash as a chemopreventive agent and for the treatment of oral dysplastic lesions. Proc Am Soc Clin Oncol 18:445a, 1999 (abstr 1715)
45. Zou Y, Zong G, Ling Y-H, et al: Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst 90:1130-1137, 1998
46. Steele VE, Moon RC, Lubet RA, et al: Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem 20S:32-54, 1994
47. Moser AR, Luongo C, Gould KA, et al: ApcMin: A mouse model for intestinal and mammary tumorigenesis. Eur J Cancer 31 A:1061-1064, 1995
48. Yang K, Edelmann W, Fan K, et al: Dietary modulation of carcinoma development in a mouse model for human familial adenomatous polyposis. Cancer Res 58:5713-5717, 1998
49. Jacoby RF, Marshall DJ, Newton MA, et al: Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56:710-714, 1996
50. Arbeit JM, Howley PM, Hanahan D: Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 93:2930-2935, 1996
51. Conney AH, Lou YR, Xie JG, et al: Some perspectives on dietary inhibition of carcinogenesis: Studies with curcumin and tea. Proc Soc Exp Biol Med 216:234-245, 1997
52. Ip C, Lisk DJ, Ganther HE: Activities of structurally-related lipophilic selenium compounds as cancer chemopreventive agents. Anticancer Res 18:4019-4025, 1998
53. Kolm RH, Danielson UH, Zhang Y, et al: Isothiocyanates as substrates for human glutathione transferases: Structure-activity studies. Biochem J 311:453-459, 1995 (Pt 2)
54. Kelloff GJ, Johnson JR, Crowell JA, et al: Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 4:1-10, 1995
55. Takayama T, Katsuki S, Takahashi Y, et al: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 339:1277-1284, 1998
56. Tearney GJ, Brezimnski ME, Bouma BE: In vivo endoscopic optical biopsy with optical coherence tomography. Science 276:2037-2039, 1997
57. Hong WK, Sporn MB: Recent advances in chemoprevention of cancer. Science 278:1073-1077, 1997
58. Lippman SM, Lee JS, Lotan R, et al: Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 82:555-560, 1990